Ismail Abeer, El-Awady Rehab, Mohamed Ghada, Hussein Marwa, Ramadan Shimaa Shwaki
Department ofClinical and Chemical pathology, National Cancer Institute, Cairo University, Egypt. Email:
Asian Pac J Cancer Prev. 2018 Feb 26;19(2):571-576. doi: 10.22034/APJCP.2018.19.2.571.
Objective: To determine the frequency and prognostic significance of vitamin D deficiency in Egyptian women with breast cancer (BC). Methods: This prospective study included 50 women with primary invasive, non-metastatic BC. The serum level of 25-hydroxy vitamin D [25(OH)D was measured by ELISA at diagnosis, before any cancer treatment. Vitamin D deficiency was defined as 25(OH) D<20 ng/mL. Patients were followed up for a median of 30 months (range: 18-48). Results: The median level of 25(OH)D was 29.0 ng/mL (range: 10.0-55.0 ng/mL). Fifteen patients (30%) had vitamin D deficiency, which was positively associated with larger tumor size (p < 0.001), higher grade (p = 0.014), advanced stage (p = 0.001), lymph node positivity (p = 0.012), and HER2/neureceptor expression (p = 0.002). It was also linked with worse overall survival (OS) and disease free survival (DFS) (p = 0.026, and p = 0.004, respectively). On multivariate analysis, DFS was independently affected by vitamin D deficiency with an HR of 2.8 (95% CI: 1.6-7.0, p = 0.022) and advanced stage, i.e. stage II had worse survival compared to stage I with an HR of 4.8 (95%CI: 1.1-21.7, p = 0.042). Conclusion: Vitamin D deficiency had a negative effect on overall and disease-free survival in our breast cancer cases, being related to tumor size, stage, grade, nodal status and HER2/neu receptor expression.
确定埃及乳腺癌(BC)女性中维生素D缺乏的频率及其预后意义。方法:这项前瞻性研究纳入了50例原发性浸润性、非转移性BC女性患者。在诊断时,即在任何癌症治疗之前,通过酶联免疫吸附测定法(ELISA)测量血清25-羟基维生素D [25(OH)D]水平。维生素D缺乏定义为25(OH)D<20 ng/mL。对患者进行了中位30个月(范围:18 - 48个月)的随访。结果:25(OH)D的中位水平为29.0 ng/mL(范围:10.0 - 55.0 ng/mL)。15例患者(30%)存在维生素D缺乏,这与更大的肿瘤大小(p < 0.001)、更高的分级(p = 0.014)、晚期阶段(p = 0.001)、淋巴结阳性(p = 0.012)以及HER2/神经受体表达(p = 0.002)呈正相关。它还与较差的总生存期(OS)和无病生存期(DFS)相关(分别为p = 0.026和p = 0.004)。多因素分析显示,DFS独立受维生素D缺乏影响,风险比(HR)为2.8(95%置信区间:1.6 - 7.0,p = 0.022)以及晚期阶段影响,即与I期相比,II期的生存期更差,HR为4.8(95%置信区间:1.1 - 21.7,p = 0.042)。结论:在我们的乳腺癌病例中,维生素D缺乏对总生存期和无病生存期有负面影响,与肿瘤大小、分期、分级、淋巴结状态及HER2/neu受体表达有关。